Consolidated Statements of Operations - USD ($) shares in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Feb. 28, 2021 |
Feb. 29, 2020 |
Feb. 28, 2021 |
Feb. 29, 2020 |
|
| Operating expenses: | ||||
| General and administrative | $ 7,902,000 | $ 6,465,000 | $ 25,328,000 | $ 12,605,000 |
| Research and development | 12,323,000 | 15,109,000 | 44,061,000 | 32,691,000 |
| Amortization and depreciation | 511,000 | 501,000 | 1,522,000 | 1,532,000 |
| Intangible asset impairment charge | 10,049,000 | 10,049,000 | ||
| Total operating expenses | 30,785,000 | 22,075,000 | 80,960,000 | 46,828,000 |
| Operating loss | (30,785,000) | (22,075,000) | (80,960,000) | (46,828,000) |
| Other income | 500,000 | 500,000 | ||
| Interest income | 1,000 | 3,000 | 2,000 | 5,000 |
| Change in fair value of derivative liabilities | (2,934,000) | (2,105,000) | ||
| Loss on extinguishment of convertible notes | (7,625,000) | (11,794,000) | ||
| Interest expense: | ||||
| Finance charges | (2,000) | (61,000) | (140,000) | (1,619,000) |
| Amortization of discount on convertible notes | (157,000) | (2,739,000) | (1,470,000) | |
| Amortization of debt issuance costs | (21,000) | (40,000) | (404,000) | |
| Inducement interest expense | (4,139,000) | (5,163,000) | (11,242,000) | (7,876,000) |
| Interest on convertible notes payable | (1,257,000) | (6,038,000) | (2,870,000) | (6,995,000) |
| Total interest expense | (5,576,000) | (11,262,000) | (17,031,000) | (18,364,000) |
| Loss before income taxes | (43,985,000) | (35,768,000) | (109,783,000) | (66,792,000) |
| Income tax benefit | 0 | 0 | 0 | 0 |
| Net loss | $ (43,985,000) | $ (35,768,000) | $ (109,783,000) | $ (66,792,000) |
| Basic and diluted loss per share | $ (0.08) | $ (0.08) | $ (0.18) | $ (0.17) |
| Basic and diluted weighted average common shares outstanding | 577,854 | 432,112 | 595,226 | 396,641 |
| X | ||||||||||
- Definition Interest and debt related expenses associated with non-operating financing activities of the entity, excluding gain (loss) on extinguishment of debt. No definition available.
|
| X | ||||||||||
- Definition Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of amortization expense attributable to debt issuance costs. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Total costs of sales and operating expenses for the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Represents the charge against earnings during the period for commitment fees and debt issuance expenses. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares. No definition available.
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of revenue and income classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). No definition available.
|